Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The peptide did not produce adverse metabolic effects associated with full-length growth hormone, including insulin resistance, glucose intolerance, or IGF-1 elevation
These include: Lifestyle interventions (dietary advice, physical activity programmes) Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available Referral to tier 3 or tier 4 weight management services , including bariatric surgery assessment where appropriate Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance
Used when the research compound is sold as a lyophilized vial
That being said, it may cause severe side effects if an allergy is present or if the individual is also taking certain medications
